United States-Abraham Accords Cooperation and Security Act of 2024

HR 7155 establishes the Abraham Accords Bureau within the FDA to strengthen U.S. healthcare supply chains. The bureau, headquartered at the FDA, will create lists of essential medical products primarily made in "covered countries" (nations with documented religious freedom violations or human rights issues) and identify facilities in Abraham Accords countries (like the UAE and Bahrain) that could support U.S. medical needs. It will facilitate FDA consultations with these countries on manufacturing standards, share regulatory information, and provide technical assistance to help shift production away from covered countries. The bureau must report to Congress within three years on progress in diversifying supply chains and improving FDA coordination with Abraham Accords nations.